Negative allosteric modulation of the mGluR5 receptor reduces repetitive behaviors and rescues social deficits in mouse models of autism
Neurodevelopmental disorders such as autism and fragile X syndrome were long thought to be medically untreatable, on the assumption that brain dysfunctions were immutably hardwired before diagnosis. Recent revelations that many cases of autism are caused by mutations in genes that control the ongoing formation and maturation of synapses have challenged this dogma. Antagonists of metabotropic glutamate receptor subtype 5 (mGluR5), which modulate excitatory neurotransmission, are in clinical trials for fragile X syndrome, a major genetic cause of intellectual disabilities. About 30% of patients with fragile X syndrome meet the diagnostic criteria for autism. Reasoning by analogy, we considered the mGluR5 receptor as a potential target for intervention in autism. We used BTBR T+tf/J (BTBR) mice, an established model with robust behavioral phenotypes relevant to the three diagnostic behavioral symptoms of autism--unusual social interactions, impaired communication, and repetitive behaviors--to probe the efficacy of a selective negative allosteric modulator of the mGluR5 receptor, GRN-529. GRN-529 reduced repetitive behaviors in three cohorts of BTBR mice at doses that did not induce sedation in control assays of open field locomotion. In addition, the same nonsedating doses reduced the spontaneous stereotyped jumping that characterizes a second inbred strain of mice, C58/J. Further, GRN-529 partially reversed the striking lack of sociability in BTBR mice on some parameters of social approach and reciprocal social interactions. These findings raise the possibility that a single targeted pharmacological intervention may alleviate multiple diagnostic behavioral symptoms of autism.
| Errataetall: |
CommentIn: Sci Transl Med. 2012 Apr 25;4(131):131fs9. - PMID 22539770 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2012 |
|---|---|
| Erschienen: |
2012 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:4 |
|---|---|
| Enthalten in: |
Science translational medicine - 4(2012), 131 vom: 25. Apr., Seite 131ra51 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Silverman, Jill L [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 21.08.2012 Date Revised 09.03.2022 published: Print CommentIn: Sci Transl Med. 2012 Apr 25;4(131):131fs9. - PMID 22539770 Citation Status MEDLINE |
|---|
| doi: |
10.1126/scitranslmed.3003501 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM217351093 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM217351093 | ||
| 003 | DE-627 | ||
| 005 | 20231224033850.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2012 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1126/scitranslmed.3003501 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0724.xml |
| 035 | |a (DE-627)NLM217351093 | ||
| 035 | |a (NLM)22539775 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Silverman, Jill L |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Negative allosteric modulation of the mGluR5 receptor reduces repetitive behaviors and rescues social deficits in mouse models of autism |
| 264 | 1 | |c 2012 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.08.2012 | ||
| 500 | |a Date Revised 09.03.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a CommentIn: Sci Transl Med. 2012 Apr 25;4(131):131fs9. - PMID 22539770 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Neurodevelopmental disorders such as autism and fragile X syndrome were long thought to be medically untreatable, on the assumption that brain dysfunctions were immutably hardwired before diagnosis. Recent revelations that many cases of autism are caused by mutations in genes that control the ongoing formation and maturation of synapses have challenged this dogma. Antagonists of metabotropic glutamate receptor subtype 5 (mGluR5), which modulate excitatory neurotransmission, are in clinical trials for fragile X syndrome, a major genetic cause of intellectual disabilities. About 30% of patients with fragile X syndrome meet the diagnostic criteria for autism. Reasoning by analogy, we considered the mGluR5 receptor as a potential target for intervention in autism. We used BTBR T+tf/J (BTBR) mice, an established model with robust behavioral phenotypes relevant to the three diagnostic behavioral symptoms of autism--unusual social interactions, impaired communication, and repetitive behaviors--to probe the efficacy of a selective negative allosteric modulator of the mGluR5 receptor, GRN-529. GRN-529 reduced repetitive behaviors in three cohorts of BTBR mice at doses that did not induce sedation in control assays of open field locomotion. In addition, the same nonsedating doses reduced the spontaneous stereotyped jumping that characterizes a second inbred strain of mice, C58/J. Further, GRN-529 partially reversed the striking lack of sociability in BTBR mice on some parameters of social approach and reciprocal social interactions. These findings raise the possibility that a single targeted pharmacological intervention may alleviate multiple diagnostic behavioral symptoms of autism | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Intramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Excitatory Amino Acid Antagonists |2 NLM | |
| 650 | 7 | |a GRM5 protein, human |2 NLM | |
| 650 | 7 | |a Grm5 protein, mouse |2 NLM | |
| 650 | 7 | |a Receptor, Metabotropic Glutamate 5 |2 NLM | |
| 650 | 7 | |a Receptors, Metabotropic Glutamate |2 NLM | |
| 700 | 1 | |a Smith, Daniel G |e verfasserin |4 aut | |
| 700 | 1 | |a Rizzo, Stacey J Sukoff |e verfasserin |4 aut | |
| 700 | 1 | |a Karras, Michael N |e verfasserin |4 aut | |
| 700 | 1 | |a Turner, Sarah M |e verfasserin |4 aut | |
| 700 | 1 | |a Tolu, Seda S |e verfasserin |4 aut | |
| 700 | 1 | |a Bryce, Dianne K |e verfasserin |4 aut | |
| 700 | 1 | |a Smith, Deborah L |e verfasserin |4 aut | |
| 700 | 1 | |a Fonseca, Kari |e verfasserin |4 aut | |
| 700 | 1 | |a Ring, Robert H |e verfasserin |4 aut | |
| 700 | 1 | |a Crawley, Jacqueline N |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Science translational medicine |d 2009 |g 4(2012), 131 vom: 25. Apr., Seite 131ra51 |w (DE-627)NLM195151879 |x 1946-6242 |7 nnns |
| 773 | 1 | 8 | |g volume:4 |g year:2012 |g number:131 |g day:25 |g month:04 |g pages:131ra51 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1126/scitranslmed.3003501 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 4 |j 2012 |e 131 |b 25 |c 04 |h 131ra51 | ||